resource,venue_year,doi_pmid,primary_scope,sequence_or_molecule,chemical_modification,delivery,target_disease,efficacy,toxicity,offtarget,provenance_audit,license_boundary,downloads_or_api,benchmark_splits,overlap_risk,oligovigil_position
theRNA,NAR 2026,DOI:10.1093/nar/gkaf1064; PMID:41171135,broad functional RNA therapeutics across RNA modalities and disease applications,yes,partial,partial,yes,yes,not_core,not_core,not_primary,unclear_from_public_record,web_resource,not_primary,medium,"Do not claim broad RNA therapeutics catalog novelty; OligoVigil should position as safety/off-target evidence with audit, downloads, and benchmark-ready release."
siRNAEfficacyDB,IET Systems Biology 2024,DOI:10.1049/syb2.12102; PMID:39541343,experimentally supported siRNA efficacy database,yes,no,no,target_gene_and_cell_context,yes,no,no,limited,open_article_cc_by,database_download,not_primary,medium,"Do not claim primary siRNA efficacy novelty; OligoVigil excludes efficacy as its main contribution and focuses on safety/off-target evidence."
CMsiRNAdb,BMC Bioinformatics 2026,DOI:10.1186/s12859-025-06359-y; PMID:41484819,chemically modified siRNA silencing efficiency from patents,yes,yes,partial,target_gene_and_cell_context,yes,not_primary,limited,curated_but_efficacy_oriented,article_cc_by_nc_nd; patent_reuse_requires_care,database_download_and_prediction,not_primary,high,"Strongest adjacent work for sequence/modification/dose fields; OligoVigil must avoid claiming complete chemistry coverage until P0 field curation is verified."
siRNAmod,RNA Biology 2016,PMCID:PMC4730238,experimentally validated chemically modified siRNAs,yes,yes,no,target_gene_and_cell_context,yes,no,limited,limited,open_pmc_article,web_resource,not_primary,medium,"Older chemistry/efficacy comparator; reinforces that OligoVigil novelty is not chemical-modification cataloging alone."
CRISPRoffT,NAR 2025,not_in_core_scope,CRISPR/Cas off-target database,guide_rna,no,no,target_context,no,no,yes,resource_specific,web_resource,web_resource,not_primary,low,"Scope exclusion; CRISPR guide off-target data are not part of OligoVigil core."
DrugBank,ongoing,licensed_database,drug knowledgebase,drug_level,partial,partial,yes,partial,partial,no,curated_database,licensed_restricted,licensed_api,no,low,"Link-out only unless license permits redistribution; not a safety/off-target oligo evidence benchmark resource."
TTD,ongoing,licensed_or_terms_review_needed,therapeutic target/drug annotations,drug_target_level,partial,no,yes,partial,partial,no,curated_database,license_review_needed,web_resource,no,low,"Useful target/drug comparator but not a release-grade oligo safety/off-target evidence benchmark."
OligoVigil,current_presubmission,local_presubmission,curator-reviewed ASO/siRNA safety and off-target evidence with provenance and benchmark splits,incomplete_curation_track,incomplete_curation_track,incomplete_curation_track,contextual,not_primary,core,core,core_release_audit,derived_annotations_only,csv_api_zip_agent_access,downloadable_A_B_reference_splits,self,"Defensible only if framed as evidence-grade safety/off-target provenance plus benchmark splits; sequence/modification/dose curation must be presented as an explicit upgrade track."